Company Overview
| Stock Name | 基石藥業 - B |
|---|---|
| Stock Code | 02616 |
| Company Full Name | 基石藥業 - B |
| Industry | 醫療保健 |
| Principal Activities | 公司主要於中國從事研發生物制藥產品。 |
| Listing Date | 2019-02-26 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市浦東新區張衡路1000號25號樓 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.cstonepharma.com |
| Share Registrar | |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 12.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 33.3% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 223,680,000 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 12.86 |
|---|---|
| First Day Open | HK$ 13.32 |
| First Day Change | 7.17% |
| First Day Volume | 57486000.0 |
| First Day Turnover | 784345000.0 |
Use of Proceeds
| Use of Proceeds | 1、預計約622.17百萬港元（相當于所得款項凈額的30.0%）將分配至以下我們 的核心候選產品； 2、預計約829.56百萬港元（相當于所得款項凈額的40.0%）將分配至以下管線 中其余八種臨床及IND階段候選藥物； 3、預計約414.78百萬港元（相當于所得款項凈額的20%）將用于為研發管線中 其余五種候選藥物以及研發和尋求新候選藥物的許可提供資金； 4、預計約207.39百萬港元（相當于所得款項凈額的10%）將用作營運資金及其 他一般公司用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (2)
高盛（亚洲）有限责任公司 CE ACC536
摩根士丹利亚洲有限公司 CE AAD291
Overall Coordinators (4)
高盛（亚洲）有限责任公司 CE ACC536
摩根士丹利亚洲有限公司 CE AAD291
UBS Securities Hong Kong Limited CE BIN466
招商证券（香港）有限公司 CE AAI650
Joint Bookrunners (4)
高盛（亚洲）有限责任公司 CE ACC536
摩根士丹利亚洲有限公司 CE AAD291
UBS Securities Hong Kong Limited CE BIN466
招商证券（香港）有限公司 CE AAI650
Joint Lead Managers (4)
高盛（亚洲）有限责任公司 CE ACC536
摩根士丹利亚洲有限公司 CE AAD291
UBS Securities Hong Kong Limited CE BIN466
招商证券（香港）有限公司 CE AAI650
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Boyu Capital Opportunities Master Fund | 156,936,000 HKD | — | 7.02% | — | 6 months | 2019-08-26 |
| 2 | GIC Private Limited | 313,872,000 HKD | — | 14.03% | — | 6 months | 2019-08-26 |
| 3 | Indus Capital Partners,LLC | 117,702,000 HKD | — | 5.26% | — | 6 months | 2019-08-26 |
| 4 | Ishana Capital Limited | 156,936,000 HKD | — | 7.02% | — | 6 months | 2019-08-26 |
Directors & Management
| Chairman | 李偉 |
|---|---|
| Company Secretary | 倪維聰 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | WuXi Healthcare Management, LLC(24.69%);Boyu Capital Fund II, L.P.(12.0%);Pfizer Corporation Hong Kong Limited(9.76%);蘇州工業園區正則健康創業投資管理中心(8.27%);新加坡政府投資有限公司(5.99%) |
|---|
